MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than merely 14.39% of US-listed equities with positive expected earnings growth.
In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -1,840.98%; that's higher than only 0.93% of US stocks.
As for revenue growth, note that MYGN's revenue has grown -24.97% over the past 12 months; that beats the revenue growth of only 11.58% of US companies in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Myriad Genetics Inc are OFIX, MMSI, ENZ, RFL, and IOSP.
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
MYGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for MYGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Myriad Genetics Inc ranked in the 14th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 84.67%. The most interesting components of our discounted cash flow analysis for Myriad Genetics Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.1% -- higher than merely 14.8% of stocks in our DCF forecasting set.
Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -19.67. This coverage rate is greater than that of just 5.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 11. This value is greater than 83.24% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Myriad Genetics Inc? See IDXX, LMNX, BSX, ELAN, and NUVA.
DUBLIN--(BUSINESS WIRE)--The "Genomics Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Market is anticipated to grow at a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications. The genomics market is geared to exponential growth
SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication. “One in six patients with prostate cancer have a hereditary form of the disease and are six times more likely to die from it within five years,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Providers with earlier knowledge of their patient’s germline status can help tailor treatments and can provide eligibility for life-sustaining therapies should they pro...